38 Baroness Morgan of Drefelin debates involving the Department of Health and Social Care

Mon 9th Nov 2026
Health Bill
Lords Chamber

Committee stage
Wed 28th Oct 2026
Health Bill
Lords Chamber

Committee stage (part one)
Fri 20th Mar 2026
Fri 16th Jan 2026
Wed 26th Nov 2025
Wed 23rd Apr 2025
Baroness Nargund Portrait Baroness Nargund (Lab)
- View Speech - Hansard - - - Excerpts

My Lords, I understand the importance of the amendments in this group and I support them. I want particularly to speak to Amendments 41 and 217, from the noble Baroness, Lady Pidgeon; Amendment 250 from the noble Baroness, Lady Finlay; and Amendment 233 from my noble friend Lady Royall.

Cancer, as we all know, is one of the leading causes of death worldwide, and it has touched many, if not most, of our lives. As the noble Baroness, Lady Pidgeon, said, one in two of us will be affected by cancer in our lifetime. We know that the Government take cancer seriously. Their national cancer plan for England, and increased investment in earlier diagnosis and clinical trials, are truly to be applauded. But the core issue is about cancer research, which I have raised before in the House, and the impact—which I have not yet addressed in the House but have in a written form—of Brexit on our ability to conduct research, to attract research fellows from across the EU and to access funding.

Before Brexit, the UK was the second-largest beneficiary of scientific research funding after Germany, and we have lost that. We have lost access to our research fellows: I used to have access to so many research fellows from the EU who came across and helped, and we did that similarly. I must declare an interest that I was a visiting professor in Belgium for nearly two decades. We exchanged research fellows, which helped enormously for original research, in particular with drugs and medicines research. We have now lost that. That is particularly relevant when it comes to rare cancers, and cancers that affect, in particular, ethnic-minority populations, because the patient population size is small, so it is not possible for NICE to conduct its cost-effectiveness and clinical effectiveness studies and come up with meaningful data to publish in high-powered scientific publications without international and EU collaboration. We desperately need that for cancer research, particularly for trials.

Cancer Research UK is an absolute star in cancer research and one of the world’s largest independent cancer research organisations, but even it has had to establish trials in other countries—partnering, for example, with the Nordic Cancer Union—because it can be cheaper, easier, faster and more accessible to do so. This means that researchers can, potentially, understand how to treat cancer more quickly and effectively elsewhere than here on our own soil, particularly when it comes to addressing prostate cancer. The noble Baroness, Lady Finlay, mentioned the importance of collaborating with the EU. We know that the EU has moved on in some ways, particularly with targeted cancer screening in high-risk patients, which is something on which we seem to be lagging behind.

I echo the call of the noble Baroness, Lady Pidgeon, in Amendment 217 for the establishment of a research and fellowship programme for international academics in cancer research, alongside appropriate visa support to enable them to come to the UK. I personally know how brilliant minds have decided to go elsewhere for their studies and research since Brexit. We are losing talent, expertise, collaboration, research staff and, potentially, treatments that could save the lives of cancer patients.

I therefore ask my noble friend the Minister, who I know takes this issue really seriously, whether the Government have given consideration to the impact of what we have lost after Brexit. How can we get more EU collaboration for cancer research and cancer research funding? What steps are the Government taking to strengthen EU and international collaboration, in particular on setting up big research trials for rare cancers and cancers affecting minority populations, and on data sharing and access to academic clinical research trials and universities across the EU? What steps are being taken to expedite the pathway from research trials to MHRA, NICE and NHS funding pathways? That is urgent, particularly for certain cancers. What more can be done to make the UK an attractive and accessible place for international researchers, research trials, and academics?

Baroness Morgan of Drefelin Portrait Baroness Morgan of Drefelin (Lab)
- View Speech - Hansard - -

My Lords, this is a very important group of amendments, which touches on all the key areas in cancer concern, including: the focus on the mandate that we are losing; the question of how to promote research; waiting times, and how incredibly stressful long waiting times are for patients; the importance of early detection and the need for screening; the importance of integrating modern approaches, such as genomic testing and personalised medicine, into daily care; and, of course, radiotherapy and the challenges facing the radiotherapy community. I support the amendments and I have added my name to Amendments 41, 217 and 228, proposed by the noble Baroness, Lady Pidgeon.

I will focus very quickly on Amendment 217 and talk a little bit about clinical trials. For me, clinical trials play an absolutely pivotal role in ensuring that outcomes for cancer patients have an upward trajectory in our new NHS. That remains central to me, and I would dearly love to hear from the Minister the reassurance that I think we need: that in following the transition, restructuring and so on, there will be an appropriate and dynamic focus on improving participation in clinical trials. Participation in clinical trials for cancer patients is falling. Although, following the O’Shaughnessy review, which was a huge wake-up call, the Government have taken important steps to tackle the amount of time it takes for clinical trials to be set up, and they have made great progress on commercial trials, we still need to do much more for academic clinical trials and those focusing on rarer cancers. That is my area of concern, and I would be grateful to hear something from the Minister on that.

As the noble Lord, Lord Hunt, has said a few times, structure needs to follow purpose. The cancer plan, the mandate from 2022 and the NHS 10-year plan are all phenomenally important commitments to improving outcomes for patients. However, if we have a hiatus because of a vacuum caused by restructuring the establishment of specialist commissioning in ICBs then are they really ready for this? Can we really be sure that all the amazing commitments in the cancer plan will be progressed further? That is really what I am looking for.

I do not think there is a lack of commitment at all on the part of the Government—the recent women’s health strategy is a great step forward—but we need to be realistic about the challenges that change creates in the system. It has taken years to develop the informal and formal ecosystem that promotes the research that we need to keep improving outcomes for patients up there on the agenda. Can the Minister please explain how we will ensure that there is a culture that really embeds the bench-to-bedside ethos that we know is so important to save lives from cancer, for rarer cancers, and for those patients experiencing cancer now but also in the future?

Baroness Ritchie of Downpatrick Portrait Baroness Ritchie of Downpatrick (Lab)
- View Speech - Hansard - - - Excerpts

My Lords, I come to this debate as someone who is a breast cancer survivor of some eight years and who has been involved in a cancer trial—a double-blind aspirin trial. I do not know whether I was taking aspirin, but I will find out next year when the results of that trial will be revealed.

I am somebody who, from practice, firmly believes in cancer outcomes. I believe there needs to be concentration on cancer outcomes, on survival and on an expeditious way to ensure that patients have ready access, especially for rare cancers. Genomics is telling us so much about the type and the content of cancer tumours that we need to work at pace to ensure that those treatments and new treatments are available to deal with them. I have every confidence that the Government will be able to facilitate that, but the challenging issues are around radiotherapy times, and the intensification of radiotherapy and those treatments.

I remember, from my first diagnosis, being told that everybody’s tumour is different, even though you may have breast cancer, because that is the collective term. Therefore, the idea and the objective is to focus that treatment on the content of the tumour that you have, which is particular to you. Treatments are dedicated to the needs of patients; I would like to think that was continued as part of our Health Bill and of treating cancer patients generally.

Baroness Campbell of Surbiton Portrait Baroness Campbell of Surbiton (CB)
- View Speech - Hansard - - - Excerpts

My Lords, I had not intended to speak in this debate, but I have been listening very closely, and I think what is missing is what happens to people at the grass roots—patients who rely on their ICBs to behave and do the right thing in terms of their care and support. When I heard that NHS England was going to shut down, I have to say that my heart went in my boots. That is because I have been working with certain departments to look at ways that we can deliver NHS personal health budgets, from when they were first conceived to now. There was an awful lot of organisational expertise, memory, support and guidance from what was then NHS England to local ICBs across the country. In doing so, personal health budgets became a good way of delivering personalised care at home for people with complex impairments. I should probably declare an interest because I have been negotiating with my ICB for about 15 years. It is not easy. What I worry about in the transition is that we do not have a plan for what is going to happen to the people in NHS England who have all that expertise, history and know-how in supporting ICBs to deliver their support to complex patients in the community in the future.

I am afraid I am not that positive, because in the last two years, since we heard that ICBs were going to make 50% savings, ICBs have been behaving quite oddly towards people with complex and sometimes expensive care in the community. They are institutionalising them even though they were supported in their own homes quite happily; for example, doing their degrees. They are restricting where you can go with your personal health budget and PA and even whether you can be outside the home, because they have told me that it is unsafe. Something odd has been in the air since we knew that NHS England was going. I believe that there were only four people left in the department supporting those ICBs with their delivery and, quite frankly, they are going backwards. I would be keen to have a plan about what is going to happen when NHS England goes. Who is going to do this work? ICBs need ongoing guidance in this area. They do not have the expertise locally, but someone has to do it.

Baroness Morgan of Drefelin Portrait Baroness Morgan of Drefelin (Lab)
- View Speech - Hansard - -

My Lords, I want to pick up some of the key points in the amendment regarding what the transition plan should look like and focus on.

I am thinking about the experience of cancer patients post the 2012 changes and what came along with them, which was the abolition of the comprehensive cancer networks that were set up around England to deliver the then cancer plan. There was a vacuum following that change, and it took years to establish the architecture that we now have in place for delivery of the current cancer plan. Given the news that NHS England is being abolished, I am really concerned that the momentum around the delivery of the current cancer plan is being impaired, so the points in Amendment 4 about setting out how the continuity of services during the transition will be maintained are important. My worries are about the cancer plan, how we will drive forward the service improvements set out in it and how all 100 recommendations will be progressed, because that is not the responsibility of any one ICB; it is currently driven forward by NHS England. How are the staff associated with that going to be transferred into the NHS? How do we make sure that there will not be a vacuum? We already had a disappointing delay in the appointment of the chair of the National Cancer Board that has been established.

We really need to make sure that this momentum continues. There is massive consensus around the cancer plan, which we should celebrate. There are 200 different types of cancer, more than 200 different types of cancer charity and many different specialities. One in two of us will get cancer at some stage in our lives. It is a massively important area for the health service, and we need to be confident that the transition will not fall between all the gaps, as it did in 2012, and then take years to re-establish the architecture that we need to deliver the ecosystem of success that we have in UK cancer services.

Terminally Ill Adults (End of Life) Bill

Baroness Morgan of Drefelin Excerpts
Amendment 166 not moved.
Baroness Morgan of Drefelin Portrait The Deputy Chairman of Committees (Baroness Morgan of Drefelin) (Lab)
- View Speech - Hansard - -

My Lords, I inform the Committee that, in the next group, we will be joined by a remote speaker. I shall call the remote speaker directly after the next amendment has been proposed.

Amendment 167

Moved by

Rare Cancers Bill

Baroness Morgan of Drefelin Excerpts
Baroness Morgan of Drefelin Portrait Baroness Morgan of Drefelin (Lab)
- View Speech - Hansard - -

My Lords, I am absolutely delighted to take part in this Second Reading debate. Although we are only a third of the way through the speakers’ list, this has already been a very moving—as well as extremely well-informed, interesting and expert—debate. Perhaps it shows the House of Lords at its best. I congratulate my noble friend on bringing forward this Private Member’s Bill and on speaking so eloquently and personally about why she is doing this.

As we have already heard, rare cancers often have lower survival rates. When we look at the number of people being diagnosed with rare cancers, “rare” gives the wrong impression, because around 52% to 55% of all cancer deaths can be attributed to rare cancers. Acute myeloid leukaemia—AML—has a five-year survival rate of just 22%. Almost 80% of those who are diagnosed with AML today will not be alive in five years’ time—that is such a tough diagnosis—and only half will survive beyond six months.

I want to pay tribute in my short remarks to the work the charities do across the sector—charities that often have no staff and are peopled by those with direct experience of loss, of the cancer type itself and of dealing with real challenges in access to treatments. Those charities often come together in the organisation, Cancer52, which I am president of. They have long been calling for more investment in research into rare and less common cancers. They do this, as we have heard already, because research is absolutely key for transforming survival rates.

These cancers are diverse, complex and affect a large patient population, but, as we have already heard it so eloquently explained by the noble Lord, Lord Patel, research is difficult in rare cancers. Populations of uniquely sequenced types of cancer are very small, so it is extremely difficult. Ideas such as those that the noble Lord presented around sequencing and repurposing all progress through greater attention and more funding for research, which the Bill aims to deliver, and will further incentivise research and investment in treatment of rare cancer types.

I am particularly interested in the provision in the Bill to appoint a national lead for rare cancers to ensure that patients are offered participation, for example, in relevant clinical trials, for far too often patients diagnosed with a rare cancer are not offered the opportunity to take part in trials. Cancer52 recently did a survey of 1,400 patients and found that 82% were not offered the opportunity to participate in a clinical trial. A Leukaemia UK research survey echoed this sentiment, finding that half of all leukaemia patients were not given the opportunity to participate in a trial.

I support the measures in the Bill. I support the need to create a focus on rare cancers, on orphan medicines and so on. I look forward to hearing from the Minister an update for the House on the work being done by the Government, through the development of plans such as the cancer plan, to tackle the real challenges of access for patients with rare cancers.

Tobacco and Vapes Bill

Baroness Morgan of Drefelin Excerpts
Baroness Hoey Portrait Baroness Hoey (Non-Afl)
- Hansard - - - Excerpts

I think it will be helpful to bring the Committee very briefly up to date on what I raised. This amendment is crucial to this Bill because it is basically about whether we can implement it because of the Windsor Framework. I thought it would be helpful for noble Lords to know that four European Union countries have now put in detailed opinions to the European Commission that His Majesty’s Government now have a few months to respond to. The spokesman for the European Union said:

“It is now for the UK in respect of Northern Ireland to report on the action it proposes to take in view of the detailed opinions. The Commission will comment on that reaction”. 


I am trying to impress again that what has gone right through this Bill is the question of whether, in the end, a generational ban can be implemented in Northern Ireland. The Minister has been told again that she has to meet me. She has been told by the Attorney-General. The Attorney-General has finally written a letter to me, not via his secretary, saying that, again, he will not be commenting, even though he is the Advocate General for Northern Ireland and the Attorney-General, and that he wants a meeting where the noble Baroness, Lady Merron, will respond to all the legal points. I thought that might be helpful. I beg to move.

Baroness Morgan of Drefelin Portrait The Deputy Chairman of Committees (Baroness Morgan of Drefelin) (Lab)
- Hansard - -

The amendment has been moved. Does anyone else want to speak to it? If no one does, then we have had the debate. Does the noble Baroness wish to withdraw the amendment?

Tobacco and Vapes Bill

Baroness Morgan of Drefelin Excerpts
Baroness Morgan of Drefelin Portrait Baroness Morgan of Drefelin (Lab)
- View Speech - Hansard - -

My Lords, I am delighted to participate in this Second Reading debate. I feel pretty clear about what we are trying to do here. This is a forward-looking Bill. It is about creating opportunities for the future, to have the next generations come through free from the dreadful impacts of tobacco on their lives. The Bill is about reducing the harms associated with tobacco and taking a broad view about that. I can understand why a trip to William Morris would—

Baroness Morgan of Drefelin Portrait Baroness Morgan of Drefelin (Lab)
- Hansard - -

Philip. I should not say William Morris, I rather like William Morris. I understand why such a trip would prompt these questions, which is what we are trying to do. I think the Bill is forward-looking, focused, proportionate and well balanced.

I want to talk, as the noble Baroness, Lady Thornton, did very movingly, about the impact that smoking has had on my family. I do not know whether I would define myself as a smoker. I certainly smoked when I was a rebellious teenager, but my family was terribly affected by the impact of smoking. My father was diagnosed with lung cancer when I was a teenager, which caused immense hardship for my family, propelled me and my sisters on to the free school meals list, queuing up with all the other children in the special school meal queue in the way we used to in the past. Both my parents went on to die prematurely of smoking-related cancer. It has been a terrible blight on my family and many thousands of families in this country. So, I am hugely in favour of the Bill.

I have enjoyed listening to colleagues from all sides of the House looking back at the journey we have been on to get here, the different debates we had in 2006 that looked at advertising and so on. We have come such a long way and it has been in the face of enormous opposition. To add my anecdote to the journey, when I first came into this House in 2004, smoking cigars and pipes in the Peers’ Guest Room was considered absolutely acceptable. As the day went by, you might bring a guest in and gradually the height of the smoke would descend to such a level that by about 5 pm you could not go in there without a gas mask. We have seen such an enormous amount of progress in tackling the blight of tobacco.

People think that tobacco—smoking—just affects the lungs, but I served as the chief executive of a breast cancer charity for a few decades and, over those years, I have seen the evidence building to show that smoking causes breast cancer as well as lung cancer and all the other impacts that we know about. Cancer Research UK now says that it causes around 2,200 breast cancers a year. So, we need to be mindful that evidence is unfolding all the time about the impact of smoking on our health.

We have heard that around four in 10 cancers in the UK are preventable and the biggest step forward we could take to prevent cancers would be to reduce cancers caused by smoking. We know that vaping, as we have heard, provides important assistance to those who want to quit smoking, and it is absolutely right that the Bill takes that into account. We know that a lot of the marketing and so on, as the noble Lord, Lord Stevens, so clearly demonstrated, is targeted at children.

I close by saying that I fully support those aspects of the Bill. I really congratulate the Government on taking seriously the terrible issues around single-use vapes. Only two weeks ago, I was in a children’s playground looking after a great-nephew. He said to me, “Do you know what? You can find a red box that can make smoke come out of your mouth—sweet smoke. It’s really great”. He is six, and he found a single-use vape in the bushes in the park and had a go on it. We do not want to see that as the norm in our society. This Bill is about the future and the kind of future that we want for our young people—I support it wholeheartedly.

Prisons: Health Services

Baroness Morgan of Drefelin Excerpts
Tuesday 14th January 2025

(1 year, 10 months ago)

Lords Chamber
Read Full debate Read Hansard Text Watch Debate Read Debate Ministerial Extracts
Asked by
Baroness Morgan of Drefelin Portrait Baroness Morgan of Drefelin
- Hansard - -

To ask His Majesty’s Government what assessment they have made of the provision of health services in prisons.

Baroness Merron Portrait The Parliamentary Under-Secretary of State, Department of Health and Social Care (Baroness Merron) (Lab)
- View Speech - Hansard - - - Excerpts

My Lords, a full health needs assessment for every prisoner is undertaken at least every three years by NHS England, which then updates service specifications and commissions appropriate services to ensure that the health needs of offenders are being met. All 19 health service specifications for prisons and other detention environments are currently being updated to ensure that they remain fit for purpose and are expected to be published by March 2026.

Baroness Morgan of Drefelin Portrait Baroness Morgan of Drefelin (Lab)
- View Speech - Hansard - -

My Lords, I thank my noble friend for her Answer. I have heard first hand, through the work of the charities the Prison Reform Trust and Revolving Doors, about the challenging and degrading experience that some prisoners have had trying to access healthcare. Does the Minister agree that there is a huge opportunity to make progress here with the development of better facilities in new prisons? Does she also agree that it be would a positive thing to include prison healthcare services in ICBs’ commissioning to ensure that people in secure settings have access to the advances and developments that are available in the community?

Baroness Merron Portrait Baroness Merron (Lab)
- View Speech - Hansard - - - Excerpts

I certainly agree with my noble friend that there are huge opportunities to improve healthcare for prisoners. On new prison design, I reassure her that all prison design will be fit for purpose because medical architects will be commissioned. That new design includes, for example, medical cells so that as many healthcare needs as possible can be met in prison. On my noble friend’s point about ICBs, it is a retained service, so it is not currently delegated to ICBs. It is the responsibility of health and justice commissioners to collaborate closely with ICBs to ensure continuity of care. The electronic referral service means that patients in prison can have access to the developments to which others in the community have access.

Puberty-suppressing Hormones

Baroness Morgan of Drefelin Excerpts
Monday 16th December 2024

(1 year, 11 months ago)

Lords Chamber
Read Full debate Read Hansard Text Watch Debate Read Debate Ministerial Extracts
Baroness Merron Portrait Baroness Merron (Lab)
- View Speech - Hansard - - - Excerpts

I very much welcome the generous and supportive comments of the noble Baroness, Lady Fox, in respect of the Secretary of State’s Statement. I am grateful for those. I note that she finds the reference to “uncapped” scary. I presented it as the way to gather the widest amount of relevant evidence, because that is a clinical trial; that is what is so important. The reason it is being done is that there is insufficient evidence and there has not been such a trial, and we need to do one for this particular situation.

In respect of meeting charities and others, the Secretary of State has been very keen to—what I would call—reset the relationship with various groups which all have different sets of thoughts on this. I have joined him in those meetings. He has also been meeting those with lived experience. We continue to do so. We have wanted to detoxify the debate, and those meetings have helped immensely. We will continue to have that listening ear.

Baroness Morgan of Drefelin Portrait Baroness Morgan of Drefelin (Lab)
- View Speech - Hansard - -

My Lords, I too welcome the Statement. The tone, as we have already heard, has been absolutely right. Thinking about the clinical trial, I would like to know a little more about the timing. If we are intending to run a clinical trial that is going to be looking at efficacy and safety, it will not be an easy trial to run and it is going to take some time. It would be really welcome if the Minister could keep the House informed, which she has already promised to do.

I am particularly interested in hearing the Minister’s view on the following point. It is really important to get this clinical trial on the puberty blockers going, but we also need to understand the value and the evidence supporting all the other interventions too—the psychosocial support, the psychological support, and all the other interventions—so that it is not just this clinical trial but a broad understanding of what really helps these young people. `

Baroness Merron Portrait Baroness Merron (Lab)
- View Speech - Hansard - - - Excerpts

My noble friend is right to raise the second point. It is a whole range of interventions, and that is certainly something that we have very much in mind for consideration, for the reasons that we have heard in the Chamber this evening and the points that my noble friend makes. In respect of timings, it is a planned pathway study and that includes a clinical trial component. It is, as I said, to build evidence. I am glad to say that it remains on track to commence recruitment early in 2025, but only after there has been ethical approval. When that is granted, that is when the final study protocol will be ready, and I know that noble Lords will have a lot of interest in that. We will be issuing further updates in early 2025, and if there are any particular questions, noble Lords are very welcome to raise them with me.

Health: Quad-demic

Baroness Morgan of Drefelin Excerpts
Tuesday 10th December 2024

(1 year, 11 months ago)

Lords Chamber
Read Full debate Read Hansard Text Watch Debate Read Debate Ministerial Extracts
Asked by
Baroness Morgan of Drefelin Portrait Baroness Morgan of Drefelin
- View Speech - Hansard - -

To ask His Majesty’s Government what steps they are taking to reduce the impact of a potential “quad-demic”, involving high prevalence of influenza, respiratory syncytial virus, COVID-19 and norovirus, following the warning of Professor Sir Stephen Powis, the NHS national medical director.

Baroness Merron Portrait The Parliamentary Under-Secretary of State, Department of Health and Social Care (Baroness Merron) (Lab)
- View Speech - Hansard - - - Excerpts

My Lords, levels of hospital admissions due to flu and norovirus are higher, while Covid hospitalisation rates are lower and RSV hospitalisation rates are about the same as the same time last year. The impact of these infectious diseases can be reduced through our annual vaccination programmes for flu and Covid-19, as well as the new year-round vaccination programme for RSV, and by observing good hygiene measures. Some 16.6 million flu vaccinations, 9.3 million Covid-19 vaccinations and 1.2 million RSV vaccinations have been delivered so far this winter.

Baroness Morgan of Drefelin Portrait Baroness Morgan of Drefelin (Lab)
- View Speech - Hansard - -

My Lords, I thank my noble friend the Minister for that comprehensive Answer. I have to say that “quad-demic” was a new phrase for me and so I was very keen to understand what the Minister made of the announcements from the NHS national medical director, Sir Stephen Powis. From my point of view, it is vital that we learn the lessons of the last pandemic and I know a huge amount of work is being done to understand the implications of the recommendations from Module 1 of the inquiry. But, as I understand it from Sir Stephen’s announcement, the uptake of NHS vaccine programmes is much lower than last year, so I am concerned for us to be reassured that if uptake does not improve in the run-up to Christmas, we are ready and we have learned the lessons from last time and we will not panic and start making foolish decisions about PPE acquisition, for example.

Baroness Merron Portrait Baroness Merron (Lab)
- View Speech - Hansard - - - Excerpts

We are absolutely committed to learning the lessons from Covid in order to build resilience. The recommendations of the independent review of procurement by Nigel Boardman have already been implemented and a Covid Counter-Fraud Commissioner has already been appointed to scrutinise contracts to learn the lessons and recover money for taxpayers. Professor Sir Stephen Powis, who I have spoken to about this, was not suggesting that there is a pandemic but more that four infectious diseases are coalescing to create a situation and that vaccination is crucial. His comments were a call to the public to get vaccinated, which I also endorse.

NHS: Breast Screening Programme

Baroness Morgan of Drefelin Excerpts
Tuesday 3rd September 2024

(2 years, 2 months ago)

Lords Chamber
Read Full debate Read Hansard Text Watch Debate Read Debate Ministerial Extracts
Asked by
Baroness Morgan of Drefelin Portrait Baroness Morgan of Drefelin
- Hansard - -

To ask His Majesty’s Government what assessment they have made of the take-up of the NHS breast screening programme.

Baroness Merron Portrait The Parliamentary Under-Secretary of State, Department of Health and Social Care (Baroness Merron) (Lab)
- View Speech - Hansard - - - Excerpts

Breast cancer survival rates have improved by 41% since the mid-1970s and 86% of women survive their cancer beyond five years. I pay tribute to NHS staff and to my noble friend Lady Morgan for making such a contribution to these improvements. Take-up of breast screening is just below 70%, and NHS England has developed a national uptake improvement plan, including expanding access to screening, reducing inequalities, improving IT systems and ensuring that communications are inclusive and accessible to all.

Baroness Morgan of Drefelin Portrait Baroness Morgan of Drefelin (Lab)
- View Speech - Hansard - -

I thank my noble friend for that very kind and generous Answer. As we know, screening uptake has been in decline for more than 10 years now. There is no NHS region that has met its 70% minimum standards since 2019-20. Importantly, uptake for women on their first invite is really worrying. Will the Minister commit to keep feet to the fire on this issue, and work closely with the department and NHS England to press down on any potential complacency because breast cancer outcomes have improved so much? Screening is a simple way to stop women dying of breast cancer, and it is not rocket science. Please can we do all we can to improve uptake?

Baroness Merron Portrait Baroness Merron (Lab)
- View Speech - Hansard - - - Excerpts

My noble friend makes a very clear and definite point about the link between breast screening and outcomes. I certainly can give her the assurance that we will continue to seek to drive up rates of breast cancer screening. It is important to say that the reason for the take-up not improving as one might have hoped since Covid is multifactored and complex, as I am sure she understands. We all know that research shows that women are more likely to attend breast screening if it is in a unit that is easy to get to, if it is convenient, and if we can help women to get over the problems of fear of the test, awkwardness or embarrassment. I give my noble friend the assurance that the NHS is working on understanding all that, and all that will be in collaboration with charities and key stakeholders.